PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30301525-1	2018	Chronic myeloid leukemia (CML) responds well to BCR-ABL tyrosine kinase inhibitors (TKI), such as imatinib and dasatinib.	Dasatinib	111-120	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	48-55